Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Robin Williams

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Addiction (Abingdon, England)|June 11, 2017
Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorderArthur Robin Williams, Julian Santaella-Tenorio, Christine M Mauro, et al.
The American Journal of Drug and Alcohol Abuse|February 22, 2024
Application of an opioid use disorder cascade of care in a large public health systemEmily Carter, Daniel Schatz, Noah Isaacs, et al.
The American Journal on Addictions|September 9, 2020
Commentary: Proposed Model State Cannabis Laws to Reduce HarmsArthur Robin Williams, Kevin P Hill, Richard N Rosenthal, et al.
Medrxiv : the Preprint Server for Health Sciences|October 31, 2023
Application of an Opioid Use Disorder Cascade of Care in a Large Public Health SystemEmily Carter, Daniel Schatz, Noah Isaacs, et al.
JAMA Health Forum|July 28, 2023
Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use DisorderArthur Robin Williams, Christopher Rowe, Ryan Gallagher, et al.
Cannabis and Cannabinoid Research|April 29, 2022
Adult Medical Cannabinoid Use and Changes in Prescription Controlled Substance UseArthur Robin Williams, Christine M Mauro, Tianshu Feng, et al.
Health Affairs Scholar|March 7, 2024
Use of in-network insurance benefits is critical for improving retention in telehealth-based buprenorphine treatmentArthur Robin Williams, Christopher Rowe, Lexie Minarik, et al.
Addiction Science & Clinical Practice|March 17, 2024
Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claimsKevin Y Xu, Alex K Gertner, Shelly F Greenfield, et al.
The American Journal of Psychiatry|May 6, 2024
Defining Discontinuation for Buprenorphine Treatment: Implications for Quality MeasurementArthur Robin Williams, Christine M Mauro, Ben Huber, et al.
Pharmacoepidemiology and Drug Safety|December 26, 2025
Identifying Extended-Release Naltrexone Treatment for Opioid Use Disorder in US Medicaid DataRachael K Ross, Anne M Butler, Marissa J Seamans, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Addiction (Abingdon, England)|June 11, 2017
Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorderArthur Robin Williams, Julian Santaella-Tenorio, Christine M Mauro, et al.
The American Journal of Drug and Alcohol Abuse|February 22, 2024
Application of an opioid use disorder cascade of care in a large public health systemEmily Carter, Daniel Schatz, Noah Isaacs, et al.
The American Journal on Addictions|September 9, 2020
Commentary: Proposed Model State Cannabis Laws to Reduce HarmsArthur Robin Williams, Kevin P Hill, Richard N Rosenthal, et al.
Medrxiv : the Preprint Server for Health Sciences|October 31, 2023
Application of an Opioid Use Disorder Cascade of Care in a Large Public Health SystemEmily Carter, Daniel Schatz, Noah Isaacs, et al.
JAMA Health Forum|July 28, 2023
Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use DisorderArthur Robin Williams, Christopher Rowe, Ryan Gallagher, et al.
Cannabis and Cannabinoid Research|April 29, 2022
Adult Medical Cannabinoid Use and Changes in Prescription Controlled Substance UseArthur Robin Williams, Christine M Mauro, Tianshu Feng, et al.
Health Affairs Scholar|March 7, 2024
Use of in-network insurance benefits is critical for improving retention in telehealth-based buprenorphine treatmentArthur Robin Williams, Christopher Rowe, Lexie Minarik, et al.
Addiction Science & Clinical Practice|March 17, 2024
Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claimsKevin Y Xu, Alex K Gertner, Shelly F Greenfield, et al.
The American Journal of Psychiatry|May 6, 2024
Defining Discontinuation for Buprenorphine Treatment: Implications for Quality MeasurementArthur Robin Williams, Christine M Mauro, Ben Huber, et al.
Pharmacoepidemiology and Drug Safety|December 26, 2025
Identifying Extended-Release Naltrexone Treatment for Opioid Use Disorder in US Medicaid DataRachael K Ross, Anne M Butler, Marissa J Seamans, et al.
Pageof 6